Encorafenib is a highly selective, ATP-competitive small-molecule BRAF inhibitor with anti-proliferative and apoptotic activity in tumor cells expressing BRAF V600E and has prolonged pharmacodynamic activity compared with other approved BRAF inhibitors5,6. This evidence concerns the gene BRAF and neoplasm.